Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $69.24 USD
Change Today 0.00 / 0.00%
Volume 0.0
TEVJF On Other Exchanges
New York
Tel Aviv
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical ind ltd (TEVJF) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/27/15 - $69.24
52 Week Low
10/6/14 - $53.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

teva pharmaceutical ind ltd (TEVJF) Details

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women’s health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Nuvigil and Provigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora/Effentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; Zecuity for the treatment of migraine in adults; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. This segment’s products in the respiratory market include ProAir, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Trisenox, Granix, Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, and Eporatio products in the oncology market. This segment also offers a portfolio of products in the women’s health category, which includes ParaGard, Plan B One-Step, and Zoely. In addition, the company provides branded over-the-counter medicines in the categories of cough/cold and allergy, digestive wellness, vitamins, minerals and supplements, analgesics, and skin medications; and sells third-party products, such as medical devices and other miscellaneous items. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Petach Tikva, Israel.

43,009 Employees
Last Reported Date: 02/9/15
Founded in 1901

teva pharmaceutical ind ltd (TEVJF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical ind ltd (TEVJF) Key Developments

European Medicines Agency Confirms Teva Pharmaceutical Industries' Successful Validation of Reslizumab Marketing Authorization Application

Teva Pharmaceutical Industries Limited announced that it has successfully filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for reslizumab. Reslizumab is a humanized anti-interleukin-5 (IL-5) monoclonal antibody (mAb) for the treatment of inadequately controlled asthma in adult patients with elevated blood eosinophils, despite an inhaled corticosteroid (ICS)-based regimen. The MAA for reslizumab includes data from Teva’s Phase III BREATH clinical trial program. The program consisted of four separate placebo-controlled Phase III trials specifically designed to include a targeted population of 1,700 adult and adolescent asthma patients with elevated blood eosinophils, whose symptoms were inadequately controlled with inhaled corticosteroid-based therapies. Results from these studies demonstrated that reslizumab, compared to placebo, reduced asthma exacerbation rates by at least half (50-60%) and provided significant improvement in lung function, quality of life and other secondary measures of asthma control as add-on therapy. Common adverse events in the reslizumab treatment group were comparable to placebo and included worsening of asthma, nasopharyngitis, upper respiratory infections, sinusitis, influenza and headache. Two anaphylactic reactions were reported and resolved following medical treatment at the study site.

Teva Pharmaceutical Industries Limited Reports Earnings Results for the Second Quarter of 2015; Provides Earnings Guidance for the Year 2015, 2016 and for the Period from the 2016 to 2018

Teva Pharmaceutical Industries Limited reported earnings results for the second quarter of 2015. For the quarter, the company reported revenues of approximately $4.97 billion, down 2% compared to the second quarter of 2014. Excluding the impact of foreign exchange fluctuations and the sale of U.S. OTC plant in July 2014, revenues increased 6% compared to the second quarter of 2014. Non-GAAP diluted earnings per share of $0.0143 in the second quarter of 2015, up 15% compared to the second quarter of 2014. Non-GAAP operating income of $1.6 billion, an increase of 16% compared to the second quarter of 2014. Cash flow from operations of $1.5 billion, an increase of 41% compared to the second quarter of 2014; free cash flow of $1.3 billion, up 51% compared to the second quarter of 2014. For the 2015, the company raised EPS guidance, reflecting the positive momentum across the business. For the full year 2015, the company expects EPS to be in the range of $5.15 to $5.40 as compared to the previously provided EPS range of $5.05 to $5.35. The company expects to achieve net profit synergies of approximately $1.5 billion annually, largely achievable by the third anniversary of the closing of the transaction. The company expects to contribute approximately $2.7 billion in EBITDA in 2016. Excluding synergies, the company expects the combination to generate pro forma revenue of $26 billion and pro forma EBITDA of $9.5 billion in 2016 and strong cash flow from operations of approximately $7.5 billion in 2016 and expect increasing cash generation going forward. During 2016 to 2018 time frame, the company expects to grow pro forma net revenues by a CAGR of 5%, pro forma EBITDA by 10.1%, pro forma cash flow from operations by 12.5% and pro forma free cash flow by 14.4%. The combined company's free cash flow will allow for rapid deleveraging and the ability to continue to pursue future acquisitions to expand portfolio in both specialty pharmaceuticals and generics.

Allergan plc, Teva Pharmaceutical Industries Limited - M&A Call

To discuss the definitive agreement under which Teva Pharmaceutical Industries Ltd. will acquire Allergan's global generic pharmaceuticals business for $40.5 billion


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVJF:US $69.24 USD 0.00

TEVJF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $51.06 USD +0.12
AbbVie Inc $70.77 USD -0.46
AstraZeneca PLC 4,191 GBp +21.00
Eli Lilly & Co $85.09 USD -0.59
Medtronic PLC $77.88 USD +0.41
View Industry Companies

Industry Analysis


Industry Average

Valuation TEVJF Industry Range
Price/Earnings 22.3x
Price/Sales 3.0x
Price/Book 2.7x
Price/Cash Flow 24.9x
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL IND LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at